Prior R, Mönning U, Schreiter-Gasser U, Weidemann A, Blennow K, Gottfries C G, Masters C L, Beyreuther K
Center for Molecular Biology, University of Heidelberg, F.R.G.
Neurosci Lett. 1991 Mar 11;124(1):69-73. doi: 10.1016/0304-3940(91)90824-d.
The major three secretory isoforms of Alzheimer beta A4 amyloid precursor protein (APP) were quantified in cerebrospinal fluid (CSF) using (1) a newly developed enzyme-linked immunosorbent assay (ELISA) and (2) densitometric analysis of CSF Western blots. The protease inhibitor-containing APP751/770 isoforms represented an average of 10.5% of total APP in CSF of patients with Alzheimer's disease (AD, n = 22), multi-infarct dementia (MID, n = 5) and normal controls (n = 10). APP levels in CSF did not depend on total CSF protein. Both findings are inconsistent with a hematogeneous origin of APP in CSF and suggest an intracerebral source. Total APP, APP695 and APP751/770 were significantly decreased in the AD and in the MID groups, but were not correlated to the ages of patients or controls.
使用（1）新开发的酶联免疫吸附测定（ELISA）和（2）脑脊液蛋白质印迹的光密度分析，对阿尔茨海默病βA4淀粉样前体蛋白（APP）的三种主要分泌同工型在脑脊液（CSF）中进行定量。含蛋白酶抑制剂的APP751/770同工型在阿尔茨海默病（AD，n = 22）、多发梗死性痴呆（MID，n = 5）患者及正常对照（n = 10）的脑脊液中平均占总APP的10.5%。脑脊液中的APP水平不依赖于脑脊液总蛋白。这两个发现均与脑脊液中APP的血液源性起源不一致，并提示其脑内来源。AD组和MID组的总APP、APP695和APP751/770均显著降低，但与患者或对照的年龄无关。
